Sun Pharma Advanced Research Company Limited — Board Meeting, 10-08-2026: Outcome of Board Meeting

SPARC's Board approved the financial results for the quarter, with a consolidated loss of ₹20.78 Cr. The board also approved reclassifying certain promoter group individuals. During the quarter, 3.85 Cr warrants were allotted preferentially at ₹155.80 each, and a licensing agreement was terminated, refunding $2M.